The Early Diagnostic and Prognostic Value of BIRC5 in Clear-Cell Renal Cell Carcinoma Based on the Cancer Genome Atlas Data

Abstract

<b><i>Purpose:</i></b> The aim of this study was to investigate the role of BIRC5 for early diagnosis and prognosis in clear-cell renal cell carcinoma (ccRCC) by studying the expression of BIRC5 and the correlation between BIRC5 expression and clinicopathological parameters and prognosis in ccRCC. <b><i>Methods:</i></b> The BIRC5 expression in ccRCC tissues and normal kidney tissues was measured using the Cancer Genome Atlas database and the Human Protein Atlas database. The correlation between BIRC5 expression and clinicopathological parameters and prognosis in ccRCC was analyzed using UALCAN, the Kaplan-Meier plotter, GEPIA, and SurvExpress. Thirteen-paired ccRCC plasma samples were used to verify the BIRC5 early diagnosis value of ccRCC. <b><i>Results:</i></b> The BIRC5 expression is significantly higher in ccRCC than in normal kidney tissues, and is correlated with the clinical stage and pathological grade of ccRCC (<i>p</i> < 0.05). The result of analyzing the relationship between BIRC5 expression and outcomes in ccRCC indicates that a high BIRC5 expression is an independent prognostic factor affecting the overall survival and disease-free survival of ccRCC (<i>p</i> < 0.05). Compared with normal kidney tissues, the immunohistochemical test shows that BIRC5 is significantly upregulated in ccRCC tissues. mRNA expression levels of BIRC5 were significantly higher in the ccRCC plasma than normal (<i>p</i> < 0.05). <b><i>Conclusions:</i></b> The high expression of BIRC5 is an important indicator for the prognosis of ccRCC, which makes BIRC5 an effective biomarker for predicting the prognosis of patients in ccRCC. BIRC5 may be a great potential biomarker for early diagnosis of ccRCC.

Long non-coding RNA SNHG3 promotes the progression of clear cell renal cell carcinoma via regulating BIRC5 expression

“…BIRC5, as a vital anti-apoptotic protein, participates in the progression of many cancers by promoting cell proliferation. Our research found that the BIRC5 gene was highly expressed in 33 malignancies, and we also validated high BIRC5 mRNA expression levels in ccRCC tissues via PCR, which corresponds with the results of other studies ( 17 ). In our study, we further demonstrated that silencing SNHG3 with siRNA could successfully prohibit BIRC5 protein expression in A498 cells.…”

A novel prognostic predictor of immune microenvironment and therapeutic response in clear cell renal cell carcinoma based on angiogenesis–immune-related gene signature

“…What's more, they have been used as prognostic models for renal clear cell carcinoma in multiple studies [ 53 , 68 ]. qRT-PCR revealed that mRNA level of CCR10 and BIRC5 were consistent with the TCGA results and this has been validated in several studies [ 69 ]. This indicates that our prognostic model genes are crucial to tumorigenesis and progression of ccRCC.…”

Identification of a Novel Defined Immune-Autophagy-Related Gene Signature Associated With Clinical and Prognostic Features of Kidney Renal Clear Cell Carcinoma

“…Baculoviral IAP repeat containing 5 (BIRC5) has been broadly studied among cancer therapeutic targets, and its main function is to suppress cell death ( Li et al, 2019 ). Numerous researches have shown that BIRC5 contributes to tumor cell immune escape by inhibiting apoptosis and confirmed that its expression is strongly correlated with prognostic status and OS in various cancers (e.g., lung, colorectal, prostate, and ovarian cancers) ( Cao et al, 2019 ; Filipchiuk et al, 2020 ; Wang et al, 2021 ). However, there are no relevant studies to explore the therapeutic effects of BIRC5 small-molecule inhibitors in tumors ( Li et al, 2019 ).…”